Sigma-Tau acquires angioedema product from Dyax
This article was originally published in Scrip
Executive Summary
Sigma-Tau's subsidiary Defiante Farmaceutica has acquired the development and commercialisation rights to Dyax's subcutaneous hereditary angioedema (HAE) treatment DX-88 (ecallantide) in Europe, North Africa, the Middle East and Russia.